WO2002030259A3 - Disease prevention by reactivation of the thymus - Google Patents

Disease prevention by reactivation of the thymus Download PDF

Info

Publication number
WO2002030259A3
WO2002030259A3 PCT/IB2001/002745 IB0102745W WO0230259A3 WO 2002030259 A3 WO2002030259 A3 WO 2002030259A3 IB 0102745 W IB0102745 W IB 0102745W WO 0230259 A3 WO0230259 A3 WO 0230259A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
thymus
patient
lhrh
gene
Prior art date
Application number
PCT/IB2001/002745
Other languages
French (fr)
Other versions
WO2002030259A9 (en
WO2002030259A2 (en
Original Assignee
Boyd Richard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPR0745A external-priority patent/AUPR074500A0/en
Priority claimed from US09/755,965 external-priority patent/US20010046486A1/en
Priority claimed from US09/965,395 external-priority patent/US20020081276A1/en
Priority to BR0114642-4A priority Critical patent/BR0114642A/en
Priority to JP2002533709A priority patent/JP2004517817A/en
Priority to EP01986582A priority patent/EP1363703A4/en
Priority to NZ525830A priority patent/NZ525830A/en
Priority to AU1632302A priority patent/AU1632302A/en
Application filed by Boyd Richard filed Critical Boyd Richard
Priority to AU2002216323A priority patent/AU2002216323C1/en
Priority to APAP/P/2003/002796A priority patent/AP2003002796A0/en
Priority to CA002462681A priority patent/CA2462681A1/en
Priority to KR10-2003-7005252A priority patent/KR20030072336A/en
Priority to IL15541401A priority patent/IL155414A0/en
Publication of WO2002030259A2 publication Critical patent/WO2002030259A2/en
Publication of WO2002030259A3 publication Critical patent/WO2002030259A3/en
Publication of WO2002030259A9 publication Critical patent/WO2002030259A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2046—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0006—Contraceptive vaccins; Vaccines against sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

The present disclosure provides methods for gene therapy utilizing hematopoietic stem cells, lymphoid progenitor cells, and/or myeloid progenitor cells. The cells are genetically modified to provide a gene that is expressed in these cells and their progeny after differentiation. In a preferred embodiment the cells contain a gene or gene fragment that confers to the cells resistance to HIV infection and/or replication. The cells are administered to a patient in conjunction with treatment to reactivate the patient's thymus. The cells may be autologous, syngeneic, allogeneic or xenogeneic, as tolerance to foreign cells is created in the patient during reactivation of the thymus. In a preferred embodiment the hematopoietic stem cells are CD34+. The patient's thymus is reactivated by disruption of sex steroid mediated signaling to the thymus. In a preferred embodiment, this disruption is created by administration of LHRH agonists, LHRH antagonists, anti-LHRH receptor antibodies, anti-LHRH vaccines or combinations thereof.
PCT/IB2001/002745 2000-10-13 2001-10-12 Disease prevention by reactivation of the thymus WO2002030259A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CA002462681A CA2462681A1 (en) 2000-10-13 2001-10-12 Disease prevention by reactivation of the thymus
KR10-2003-7005252A KR20030072336A (en) 2000-10-13 2001-10-12 Disease prevention by reactivation of the thymus
IL15541401A IL155414A0 (en) 2000-10-13 2001-10-12 Disease prevention by reactivation of the thymus
APAP/P/2003/002796A AP2003002796A0 (en) 2000-10-13 2001-10-12 Disease prevention by reactivation of the thymus
EP01986582A EP1363703A4 (en) 2000-10-13 2001-10-12 Disease prevention by reactivation of the thymus
NZ525830A NZ525830A (en) 2000-10-13 2001-10-12 Disease prevention by reactivation of the thymus
AU1632302A AU1632302A (en) 2000-10-13 2001-10-12 Disease prevention by reactivation of the thymus
BR0114642-4A BR0114642A (en) 2000-10-13 2001-10-12 Disease prevention through thymus reactivation
AU2002216323A AU2002216323C1 (en) 2000-10-13 2001-10-12 Disease prevention by reactivation of the thymus
JP2002533709A JP2004517817A (en) 2000-10-13 2001-10-12 Prevent disease by reactivating the thymus

Applications Claiming Priority (16)

Application Number Priority Date Filing Date Title
US79530200A 2000-10-13 2000-10-13
US79528600A 2000-10-13 2000-10-13
AUPR0745A AUPR074500A0 (en) 2000-10-13 2000-10-13 Treatment of t cell disorders
AUPR0745 2000-10-13
US09/795,302 2000-10-13
US09/795,286 2000-10-13
US75564601A 2001-01-05 2001-01-05
US75598301A 2001-01-05 2001-01-05
US09/755,965 2001-01-05
US09/755,983 2001-01-05
US09/755,965 US20010046486A1 (en) 2000-04-17 2001-01-05 Stimulation of thymus for vaccination development
US09/755,646 2001-01-05
US75891001A 2001-01-10 2001-01-10
US09/758,910 2001-01-10
US09/965,395 US20020081276A1 (en) 1999-04-15 2001-09-26 Disease prevention by reactivation of the thymus
US09/965,395 2001-09-26

Publications (3)

Publication Number Publication Date
WO2002030259A2 WO2002030259A2 (en) 2002-04-18
WO2002030259A3 true WO2002030259A3 (en) 2002-07-04
WO2002030259A9 WO2002030259A9 (en) 2003-08-07

Family

ID=27570138

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2001/002745 WO2002030259A2 (en) 2000-10-13 2001-10-12 Disease prevention by reactivation of the thymus

Country Status (9)

Country Link
EP (1) EP1363703A4 (en)
CN (1) CN100406025C (en)
AP (1) AP2003002796A0 (en)
AU (1) AU1632302A (en)
BR (1) BR0114642A (en)
CA (1) CA2462681A1 (en)
IL (1) IL155414A0 (en)
NZ (1) NZ525830A (en)
WO (1) WO2002030259A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004094599A2 (en) * 2003-04-18 2004-11-04 Norwood Immunology, Ltd. Disease prevention and vaccination following thymic reactivation
JP2010539015A (en) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト Use of IL-1 receptor peptide alone or in combination with D-Ala-Gln-octadecyl ester as therapeutic agent
WO2011020047A1 (en) 2009-08-14 2011-02-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of il-15 to increase thymic output and to treat lymphopenia
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
SG2014011670A (en) 2011-10-21 2014-10-30 Abbvie Inc Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv
CN103826627B (en) 2011-10-21 2016-02-24 艾伯维公司 Comprise the purposes of compositions in the medicine of preparation treatment HCV of at least two kinds of direct antiviral agent and ribavirin
EA201892448A1 (en) 2016-04-28 2019-06-28 Эмори Юниверсити ALKYN-CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND RELATED APPLICATION METHODS

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000062657A2 (en) * 1999-04-15 2000-10-26 Monash University Improvement of t cell mediated immunity

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4049805A (en) * 1975-09-30 1977-09-20 Akzona Incorporated Steroidal erythropoietic agents and therapeutic compositions and methods
CN1058500C (en) * 1993-02-03 2000-11-15 施塞克龙药品公司 Thymosin alpha-1 derivatives
JP3553941B2 (en) * 1993-05-17 2004-08-11 ザ ジェネラル ホスピタル コーポレイション Xenograft thymus
AUPP971499A0 (en) * 1999-04-12 1999-05-06 Opentec Pty. Limited On-line electoral system

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000062657A2 (en) * 1999-04-15 2000-10-26 Monash University Improvement of t cell mediated immunity

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BONYHADI M. ET AL: "RevM10-expressing T cells derived in vivo from transduced human hematopoietic stem-progenitor cells inhibit human immunodeficiency virus replication", J. VIROL., vol. 71, no. 6, 1997, pages 4707 - 4716, XP002971217 *
FABRIS N. ET AL: "Plasticity of neuro-endocrine-thymus interaction during aging", CELLULAR AND MOLEC. BIOL., vol. 43, no. 4, 1997, pages 529 - 541, XP002972504 *
GREENSTEIN B. ET AL: "Regeneration of the thymus in old male rats treated with a stable analogue of LHRH", J. ENDOCR., vol. 112, 1987, pages 345 - 350, XP002972503 *
NIKOLIC B. ET AL.: "A novel application of cyclosporin A in nonmyeloablative pretransplant host conditioning for allogeneic BMT", BLOOD, vol. 96, no. 3, August 2000 (2000-08-01), pages 1166 - 1172, XP002971216 *
PENIT C. ET AL: "Cell proliferation and thymocyte subset reconstitution in sublethally irradiated mice: Compared kinetics of endogenous and intrathymically transferred progenitors", PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 5547 - 5551, XP002971775 *
WINDMILL K. ET AL: "Effects of castration on the lymphocytes of the thymus, spleen and lymph node", TISSUE & CELL, vol. 30, no. 1, 1998, pages 104 - 111, XP009023772 *
WINDMILL K. ET AL: "Influences of surgical castration on the thymus of male rats", J. REPROD. IMMUN., vol. 44, 1999, pages 29 - 39, XP002971218 *

Also Published As

Publication number Publication date
CA2462681A1 (en) 2002-04-18
AP2003002796A0 (en) 2003-06-30
WO2002030259A9 (en) 2003-08-07
WO2002030259A2 (en) 2002-04-18
CN1505537A (en) 2004-06-16
AU1632302A (en) 2002-04-22
NZ525830A (en) 2005-07-29
CN100406025C (en) 2008-07-30
EP1363703A2 (en) 2003-11-26
BR0114642A (en) 2004-01-20
EP1363703A4 (en) 2006-06-07
IL155414A0 (en) 2003-11-23

Similar Documents

Publication Publication Date Title
Han et al. The secretion profile of mesenchymal stem cells and potential applications in treating human diseases
AU2020201856A1 (en) Methods modulating immunoregulatory effect of stem cells
Anrather et al. Inflammation and stroke: an overview
Kim et al. Mesenchymal stem cells for the treatment and prevention of graft-versus-host disease: experiments and practice
Bonsack et al. Mesenchymal stem cell therapy alleviates the neuroinflammation associated with acquired brain injury
Khan et al. A comparison of phenotypic and functional properties of mesenchymal stromal cells and multipotent adult progenitor cells
CN104095878B (en) Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
ES2623141T3 (en) New methods to modulate inflammatory and / or immune responses
US20240269188A1 (en) Methods for inducing an immune response by administering activated mesenchymal stem cells
JP2004521877A5 (en)
WO2006078782A3 (en) Compositions containing agm cells and methods of use thereof
WO2002030259A3 (en) Disease prevention by reactivation of the thymus
Sadeghi et al. Mesenchymal stromal cells as treatment for acute respiratory distress syndrome. Case Reports following hematopoietic cell transplantation and a review
US20020142462A1 (en) Methods for mobilizing hematopoietic facilitating cells and hematopoietic stem cells into the peripheral blood
WO2002031110A3 (en) Hematopoietic stem cell gene therapy
Dudakov et al. Greater than the sum of their parts: combination strategies for immune regeneration following allogeneic hematopoietic stem cell transplantation
Saad-Naguib et al. Impaired receptivity of thin endometrium: therapeutic potential of mesenchymal stem cells
Saidi et al. Utilization of Mesenchymal Stem Cells in Kidney Transplantation: From Bench to Bedside.
Yoshioka et al. Human mesenchymal stem cell therapy for acute graft versus host disease
WO2002030257A3 (en) Normalization of defective t cell responsiveness through manipulation of thymic regeneration
EP3895713A1 (en) Methods for mobilizing stem cells
Park et al. Human umbilical cord blood stem cells rescue ischemic tissues
Hayashi et al. Olle Ringdén 1*, Britt Gustafsson2 and Behnam Sadeghi
KR101705378B1 (en) Composition for Preventing or Treating Graft-Versus-Host Disease Comprising Mesenchymal Stem Cell and IL-21 inhibitor
Boregowda et al. Reconciling the stem cell and paracrine paradigms of mesenchymal stem cell function

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002533709

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 155414

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1020037005252

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2001986582

Country of ref document: EP

Ref document number: 2003/03686

Country of ref document: ZA

Ref document number: 2002216323

Country of ref document: AU

Ref document number: 525830

Country of ref document: NZ

Ref document number: 200303686

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: AP/P/2003/002796

Country of ref document: AP

WWE Wipo information: entry into national phase

Ref document number: 018201342

Country of ref document: CN

COP Corrected version of pamphlet

Free format text: PAGES 1/34-34/34, DRAWINGS, REPLACED BY NEW PAGES 1/27-27/27; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020037005252

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2001986582

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2462681

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 525830

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 525830

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2002216323

Country of ref document: AU

Date of ref document: 20011012

Kind code of ref document: B